nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A4—bone cancer	0.715	1	CbGaD
Ondansetron—HTR1B—dura mater—bone cancer	0.0102	0.388	CbGeAlD
Ondansetron—Alosetron—CYP3A4—bone cancer	0.00833	1	CrCbGaD
Ondansetron—HTR1B—trigeminal nerve—bone cancer	0.00438	0.167	CbGeAlD
Ondansetron—HTR3A—cranial nerve—bone cancer	0.00372	0.142	CbGeAlD
Ondansetron—HTR1B—cranial nerve—bone cancer	0.00312	0.119	CbGeAlD
Ondansetron—SLC47A2—tendon—bone cancer	0.00148	0.0564	CbGeAlD
Ondansetron—Feeling hot—Epirubicin—bone cancer	0.00103	0.00702	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.00103	0.00701	CcSEcCtD
Ondansetron—Injection site pain—Epirubicin—bone cancer	0.000992	0.00675	CcSEcCtD
Ondansetron—Feeling hot—Doxorubicin—bone cancer	0.000955	0.00649	CcSEcCtD
Ondansetron—Neoplasm malignant—Epirubicin—bone cancer	0.000949	0.00645	CcSEcCtD
Ondansetron—Cardiovascular disorder—Epirubicin—bone cancer	0.000922	0.00627	CcSEcCtD
Ondansetron—Injection site pain—Doxorubicin—bone cancer	0.000918	0.00624	CcSEcCtD
Ondansetron—Ventricular extrasystoles—Epirubicin—bone cancer	0.000897	0.0061	CcSEcCtD
Ondansetron—Neoplasm malignant—Doxorubicin—bone cancer	0.000878	0.00597	CcSEcCtD
Ondansetron—Acute coronary syndrome—Cisplatin—bone cancer	0.00087	0.00591	CcSEcCtD
Ondansetron—Myocardial infarction—Cisplatin—bone cancer	0.000865	0.00588	CcSEcCtD
Ondansetron—Dyskinesia—Epirubicin—bone cancer	0.000862	0.00586	CcSEcCtD
Ondansetron—Cardiovascular disorder—Doxorubicin—bone cancer	0.000853	0.0058	CcSEcCtD
Ondansetron—Hepatobiliary disease—Cisplatin—bone cancer	0.000835	0.00567	CcSEcCtD
Ondansetron—Ventricular extrasystoles—Doxorubicin—bone cancer	0.00083	0.00564	CcSEcCtD
Ondansetron—Musculoskeletal pain—Epirubicin—bone cancer	0.00082	0.00558	CcSEcCtD
Ondansetron—Hepatocellular injury—Epirubicin—bone cancer	0.00081	0.00551	CcSEcCtD
Ondansetron—Hiccups—Epirubicin—bone cancer	0.00081	0.00551	CcSEcCtD
Ondansetron—Bradycardia—Cisplatin—bone cancer	0.000807	0.00548	CcSEcCtD
Ondansetron—Injection site reaction—Epirubicin—bone cancer	0.000805	0.00548	CcSEcCtD
Ondansetron—Dyskinesia—Doxorubicin—bone cancer	0.000798	0.00542	CcSEcCtD
Ondansetron—Visual impairment—Cisplatin—bone cancer	0.000763	0.00519	CcSEcCtD
Ondansetron—Musculoskeletal pain—Doxorubicin—bone cancer	0.000759	0.00516	CcSEcCtD
Ondansetron—Hepatocellular injury—Doxorubicin—bone cancer	0.00075	0.0051	CcSEcCtD
Ondansetron—Hiccups—Doxorubicin—bone cancer	0.00075	0.0051	CcSEcCtD
Ondansetron—Injection site reaction—Doxorubicin—bone cancer	0.000745	0.00507	CcSEcCtD
Ondansetron—Eye disorder—Cisplatin—bone cancer	0.00074	0.00503	CcSEcCtD
Ondansetron—Cardiac disorder—Cisplatin—bone cancer	0.000735	0.005	CcSEcCtD
Ondansetron—Flushing—Cisplatin—bone cancer	0.000735	0.005	CcSEcCtD
Ondansetron—Immune system disorder—Cisplatin—bone cancer	0.000716	0.00487	CcSEcCtD
Ondansetron—Mediastinal disorder—Cisplatin—bone cancer	0.000714	0.00485	CcSEcCtD
Ondansetron—Arrhythmia—Cisplatin—bone cancer	0.000708	0.00481	CcSEcCtD
Ondansetron—Hepatic failure—Methotrexate—bone cancer	0.000699	0.00475	CcSEcCtD
Ondansetron—Erythema—Cisplatin—bone cancer	0.00069	0.00469	CcSEcCtD
Ondansetron—Flatulence—Cisplatin—bone cancer	0.00068	0.00462	CcSEcCtD
Ondansetron—Visual disturbance—Methotrexate—bone cancer	0.000663	0.00451	CcSEcCtD
Ondansetron—Hepatic failure—Epirubicin—bone cancer	0.000654	0.00445	CcSEcCtD
Ondansetron—Vision blurred—Cisplatin—bone cancer	0.00065	0.00442	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Methotrexate—bone cancer	0.000649	0.00441	CcSEcCtD
Ondansetron—Tremor—Cisplatin—bone cancer	0.000646	0.00439	CcSEcCtD
Ondansetron—Ill-defined disorder—Cisplatin—bone cancer	0.00064	0.00435	CcSEcCtD
Ondansetron—Malaise—Cisplatin—bone cancer	0.000622	0.00423	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Epirubicin—bone cancer	0.000608	0.00413	CcSEcCtD
Ondansetron—Hepatic failure—Doxorubicin—bone cancer	0.000606	0.00412	CcSEcCtD
Ondansetron—Convulsion—Cisplatin—bone cancer	0.000598	0.00406	CcSEcCtD
Ondansetron—Anxiety—Cisplatin—bone cancer	0.000585	0.00398	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000583	0.00396	CcSEcCtD
Ondansetron—Liver function test abnormal—Methotrexate—bone cancer	0.00058	0.00394	CcSEcCtD
Ondansetron—Discomfort—Cisplatin—bone cancer	0.00058	0.00394	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000566	0.00385	CcSEcCtD
Ondansetron—Anaphylactic shock—Cisplatin—bone cancer	0.000563	0.00383	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000562	0.00382	CcSEcCtD
Ondansetron—Nervous system disorder—Cisplatin—bone cancer	0.000552	0.00375	CcSEcCtD
Ondansetron—Tachycardia—Cisplatin—bone cancer	0.000549	0.00373	CcSEcCtD
Ondansetron—Skin disorder—Cisplatin—bone cancer	0.000547	0.00372	CcSEcCtD
Ondansetron—Asthma—Methotrexate—bone cancer	0.000543	0.00369	CcSEcCtD
Ondansetron—Liver function test abnormal—Epirubicin—bone cancer	0.000543	0.00369	CcSEcCtD
Ondansetron—Hypokalaemia—Epirubicin—bone cancer	0.000535	0.00364	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00053	0.0036	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.00053	0.0036	CcSEcCtD
Ondansetron—Hypotension—Cisplatin—bone cancer	0.000526	0.00358	CcSEcCtD
Ondansetron—SLC47A1—tendon—bone cancer	0.000519	0.0197	CbGeAlD
Ondansetron—Asthma—Epirubicin—bone cancer	0.000508	0.00346	CcSEcCtD
Ondansetron—Dysuria—Methotrexate—bone cancer	0.000508	0.00345	CcSEcCtD
Ondansetron—Paraesthesia—Cisplatin—bone cancer	0.000505	0.00344	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—bone cancer	0.000502	0.00342	CcSEcCtD
Ondansetron—Dyspnoea—Cisplatin—bone cancer	0.000502	0.00341	CcSEcCtD
Ondansetron—SLC47A1—spinal cord—bone cancer	0.0005	0.019	CbGeAlD
Ondansetron—Hypokalaemia—Doxorubicin—bone cancer	0.000495	0.00337	CcSEcCtD
Ondansetron—Angina pectoris—Epirubicin—bone cancer	0.000495	0.00337	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00049	0.00333	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00049	0.00333	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Cisplatin—bone cancer	0.000486	0.0033	CcSEcCtD
Ondansetron—Drowsiness—Methotrexate—bone cancer	0.000484	0.00329	CcSEcCtD
Ondansetron—Pain—Cisplatin—bone cancer	0.000481	0.00327	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00048	0.00326	CcSEcCtD
Ondansetron—Dysuria—Epirubicin—bone cancer	0.000475	0.00323	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—bone cancer	0.00047	0.0032	CcSEcCtD
Ondansetron—OPRM1—spinal cord—bone cancer	0.000467	0.0178	CbGeAlD
Ondansetron—Feeling abnormal—Cisplatin—bone cancer	0.000464	0.00315	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—bone cancer	0.000458	0.00311	CcSEcCtD
Ondansetron—Hepatobiliary disease—Methotrexate—bone cancer	0.000458	0.00311	CcSEcCtD
Ondansetron—Drowsiness—Epirubicin—bone cancer	0.000453	0.00308	CcSEcCtD
Ondansetron—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000453	0.00438	CbGpPWpGaD
Ondansetron—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000449	0.00305	CcSEcCtD
Ondansetron—Body temperature increased—Cisplatin—bone cancer	0.000445	0.00303	CcSEcCtD
Ondansetron—Urinary tract infection—Epirubicin—bone cancer	0.000441	0.003	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—bone cancer	0.00044	0.00299	CcSEcCtD
Ondansetron—Haemoglobin—Methotrexate—bone cancer	0.000437	0.00297	CcSEcCtD
Ondansetron—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000436	0.00421	CbGpPWpGaD
Ondansetron—Haemorrhage—Methotrexate—bone cancer	0.000435	0.00296	CcSEcCtD
Ondansetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000431	0.00417	CbGpPWpGaD
Ondansetron—Hepatobiliary disease—Epirubicin—bone cancer	0.000429	0.00291	CcSEcCtD
Ondansetron—HTR1B—spinal cord—bone cancer	0.000427	0.0163	CbGeAlD
Ondansetron—Drowsiness—Doxorubicin—bone cancer	0.000419	0.00285	CcSEcCtD
Ondansetron—Visual impairment—Methotrexate—bone cancer	0.000419	0.00285	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000416	0.00283	CcSEcCtD
Ondansetron—HTR4—GPCR ligand binding—SMO—bone cancer	0.000415	0.00401	CbGpPWpGaD
Ondansetron—Hypersensitivity—Cisplatin—bone cancer	0.000415	0.00282	CcSEcCtD
Ondansetron—Bradycardia—Epirubicin—bone cancer	0.000414	0.00282	CcSEcCtD
Ondansetron—OPRM1—G alpha (i) signalling events—GRM4—bone cancer	0.000414	0.004	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—RGS1—bone cancer	0.000414	0.004	CbGpPWpGaD
Ondansetron—Erythema multiforme—Methotrexate—bone cancer	0.000411	0.00279	CcSEcCtD
Ondansetron—HTR3A—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00041	0.00396	CbGpPWpGaD
Ondansetron—Haemoglobin—Epirubicin—bone cancer	0.000409	0.00278	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—bone cancer	0.000408	0.00277	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—bone cancer	0.000407	0.00277	CcSEcCtD
Ondansetron—Eye disorder—Methotrexate—bone cancer	0.000406	0.00276	CcSEcCtD
Ondansetron—Asthenia—Cisplatin—bone cancer	0.000404	0.00275	CcSEcCtD
Ondansetron—Cardiac disorder—Methotrexate—bone cancer	0.000403	0.00274	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—bone cancer	0.000397	0.0027	CcSEcCtD
Ondansetron—Angiopathy—Methotrexate—bone cancer	0.000394	0.00268	CcSEcCtD
Ondansetron—Immune system disorder—Methotrexate—bone cancer	0.000393	0.00267	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—bone cancer	0.000392	0.00267	CcSEcCtD
Ondansetron—Mediastinal disorder—Methotrexate—bone cancer	0.000392	0.00266	CcSEcCtD
Ondansetron—Chills—Methotrexate—bone cancer	0.00039	0.00265	CcSEcCtD
Ondansetron—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000389	0.00376	CbGpPWpGaD
Ondansetron—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000389	0.00376	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000388	0.00375	CbGpPWpGaD
Ondansetron—Diarrhoea—Cisplatin—bone cancer	0.000385	0.00262	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—bone cancer	0.000385	0.00262	CcSEcCtD
Ondansetron—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000384	0.00371	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—GRM4—bone cancer	0.000384	0.00371	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—RGS1—bone cancer	0.000384	0.00371	CbGpPWpGaD
Ondansetron—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000383	0.00371	CbGpPWpGaD
Ondansetron—Bradycardia—Doxorubicin—bone cancer	0.000383	0.00261	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—bone cancer	0.00038	0.00258	CcSEcCtD
Ondansetron—Erythema—Methotrexate—bone cancer	0.000378	0.00257	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—bone cancer	0.000378	0.00257	CcSEcCtD
Ondansetron—Flushing—Epirubicin—bone cancer	0.000378	0.00257	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—bone cancer	0.000378	0.00257	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—bone cancer	0.000376	0.00256	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—bone cancer	0.000369	0.00251	CcSEcCtD
Ondansetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000369	0.00356	CbGpPWpGaD
Ondansetron—Immune system disorder—Epirubicin—bone cancer	0.000367	0.0025	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—bone cancer	0.000367	0.00249	CcSEcCtD
Ondansetron—Chills—Epirubicin—bone cancer	0.000365	0.00248	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—bone cancer	0.000363	0.00247	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—bone cancer	0.000363	0.00247	CcSEcCtD
Ondansetron—Vomiting—Cisplatin—bone cancer	0.000358	0.00243	CcSEcCtD
Ondansetron—HTR1A—G alpha (i) signalling events—GRM4—bone cancer	0.000357	0.00345	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—RGS1—bone cancer	0.000357	0.00345	CbGpPWpGaD
Ondansetron—Vision blurred—Methotrexate—bone cancer	0.000357	0.00242	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—bone cancer	0.000356	0.00242	CcSEcCtD
Ondansetron—Rash—Cisplatin—bone cancer	0.000355	0.00241	CcSEcCtD
Ondansetron—Dermatitis—Cisplatin—bone cancer	0.000355	0.00241	CcSEcCtD
Ondansetron—Erythema—Epirubicin—bone cancer	0.000354	0.00241	CcSEcCtD
Ondansetron—HTR3A—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000354	0.00342	CbGpPWpGaD
Ondansetron—Eye disorder—Doxorubicin—bone cancer	0.000352	0.00239	CcSEcCtD
Ondansetron—Ill-defined disorder—Methotrexate—bone cancer	0.000351	0.00239	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—bone cancer	0.000349	0.00238	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—bone cancer	0.000349	0.00238	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—bone cancer	0.000349	0.00237	CcSEcCtD
Ondansetron—HTR4—Signaling by GPCR—GRM4—bone cancer	0.000349	0.00337	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—RGS1—bone cancer	0.000349	0.00337	CbGpPWpGaD
Ondansetron—HTR1A—spinal cord—bone cancer	0.000345	0.0131	CbGeAlD
Ondansetron—Angiopathy—Doxorubicin—bone cancer	0.000342	0.00232	CcSEcCtD
Ondansetron—Malaise—Methotrexate—bone cancer	0.000341	0.00232	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—bone cancer	0.00034	0.00231	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—bone cancer	0.000339	0.00231	CcSEcCtD
Ondansetron—Chills—Doxorubicin—bone cancer	0.000338	0.0023	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—bone cancer	0.000336	0.00229	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—bone cancer	0.000334	0.00227	CcSEcCtD
Ondansetron—HTR4—GPCR downstream signaling—GRM1—bone cancer	0.000333	0.00322	CbGpPWpGaD
Ondansetron—Cough—Methotrexate—bone cancer	0.00033	0.00225	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—bone cancer	0.000329	0.00223	CcSEcCtD
Ondansetron—Convulsion—Methotrexate—bone cancer	0.000328	0.00223	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—bone cancer	0.000328	0.00223	CcSEcCtD
Ondansetron—Agitation—Epirubicin—bone cancer	0.000325	0.00221	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—bone cancer	0.000323	0.0022	CcSEcCtD
Ondansetron—Chest pain—Methotrexate—bone cancer	0.000322	0.00219	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00032	0.00218	CcSEcCtD
Ondansetron—Malaise—Epirubicin—bone cancer	0.000319	0.00217	CcSEcCtD
Ondansetron—Discomfort—Methotrexate—bone cancer	0.000318	0.00216	CcSEcCtD
Ondansetron—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000318	0.00307	CbGpPWpGaD
Ondansetron—Syncope—Epirubicin—bone cancer	0.000318	0.00216	CcSEcCtD
Ondansetron—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000316	0.00305	CbGpPWpGaD
Ondansetron—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000315	0.00305	CbGpPWpGaD
Ondansetron—Palpitations—Epirubicin—bone cancer	0.000313	0.00213	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—bone cancer	0.000311	0.00212	CcSEcCtD
Ondansetron—Cough—Epirubicin—bone cancer	0.000309	0.0021	CcSEcCtD
Ondansetron—Anaphylactic shock—Methotrexate—bone cancer	0.000309	0.0021	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—bone cancer	0.000309	0.0021	CcSEcCtD
Ondansetron—KCNH2—bone marrow—bone cancer	0.000308	0.0117	CbGeAlD
Ondansetron—KCNH2—spinal cord—bone cancer	0.000307	0.0117	CbGeAlD
Ondansetron—Convulsion—Epirubicin—bone cancer	0.000307	0.00209	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—bone cancer	0.000304	0.00207	CcSEcCtD
Ondansetron—Nervous system disorder—Methotrexate—bone cancer	0.000303	0.00206	CcSEcCtD
Ondansetron—HTR4—Signaling by GPCR—GRM1—bone cancer	0.000302	0.00292	CbGpPWpGaD
Ondansetron—Chest pain—Epirubicin—bone cancer	0.000302	0.00205	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—bone cancer	0.000301	0.00205	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—bone cancer	0.0003	0.00204	CcSEcCtD
Ondansetron—Skin disorder—Methotrexate—bone cancer	0.0003	0.00204	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000299	0.00204	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—bone cancer	0.000298	0.00203	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—bone cancer	0.000296	0.00201	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—bone cancer	0.000295	0.002	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—bone cancer	0.000294	0.002	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—bone cancer	0.00029	0.00197	CcSEcCtD
Ondansetron—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000289	0.0028	CbGpPWpGaD
Ondansetron—Anaphylactic shock—Epirubicin—bone cancer	0.000289	0.00197	CcSEcCtD
Ondansetron—Hypotension—Methotrexate—bone cancer	0.000289	0.00196	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—bone cancer	0.000288	0.00196	CcSEcCtD
Ondansetron—Cough—Doxorubicin—bone cancer	0.000286	0.00194	CcSEcCtD
Ondansetron—Shock—Epirubicin—bone cancer	0.000284	0.00193	CcSEcCtD
Ondansetron—HTR1B—GPCR ligand binding—GRM4—bone cancer	0.000284	0.00275	CbGpPWpGaD
Ondansetron—Convulsion—Doxorubicin—bone cancer	0.000284	0.00193	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—bone cancer	0.000283	0.00193	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—bone cancer	0.000282	0.00192	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—bone cancer	0.000281	0.00191	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—bone cancer	0.000279	0.0019	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—bone cancer	0.000278	0.00189	CcSEcCtD
Ondansetron—Paraesthesia—Methotrexate—bone cancer	0.000277	0.00189	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000277	0.00188	CcSEcCtD
Ondansetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000276	0.00267	CbGpPWpGaD
Ondansetron—Discomfort—Doxorubicin—bone cancer	0.000276	0.00187	CcSEcCtD
Ondansetron—Dyspnoea—Methotrexate—bone cancer	0.000275	0.00187	CcSEcCtD
Ondansetron—Somnolence—Methotrexate—bone cancer	0.000275	0.00187	CcSEcCtD
Ondansetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000274	0.00265	CbGpPWpGaD
Ondansetron—Dry mouth—Doxorubicin—bone cancer	0.000273	0.00186	CcSEcCtD
Ondansetron—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000273	0.00264	CbGpPWpGaD
Ondansetron—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00027	0.00261	CbGpPWpGaD
Ondansetron—Hypotension—Epirubicin—bone cancer	0.00027	0.00184	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—bone cancer	0.000267	0.00182	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Methotrexate—bone cancer	0.000267	0.00181	CcSEcCtD
Ondansetron—Fatigue—Methotrexate—bone cancer	0.000266	0.00181	CcSEcCtD
Ondansetron—Pain—Methotrexate—bone cancer	0.000264	0.0018	CcSEcCtD
Ondansetron—Shock—Doxorubicin—bone cancer	0.000263	0.00179	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—bone cancer	0.000262	0.00178	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—bone cancer	0.000261	0.00177	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—bone cancer	0.00026	0.00177	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—bone cancer	0.00026	0.00176	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—bone cancer	0.000258	0.00175	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—bone cancer	0.000257	0.00175	CcSEcCtD
Ondansetron—Feeling abnormal—Methotrexate—bone cancer	0.000255	0.00173	CcSEcCtD
Ondansetron—Gastrointestinal pain—Methotrexate—bone cancer	0.000253	0.00172	CcSEcCtD
Ondansetron—OPRM1—GPCR ligand binding—GRM4—bone cancer	0.000251	0.00242	CbGpPWpGaD
Ondansetron—Hypotension—Doxorubicin—bone cancer	0.00025	0.0017	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—bone cancer	0.00025	0.0017	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—bone cancer	0.000249	0.00169	CcSEcCtD
Ondansetron—Constipation—Epirubicin—bone cancer	0.000247	0.00168	CcSEcCtD
Ondansetron—Pain—Epirubicin—bone cancer	0.000247	0.00168	CcSEcCtD
Ondansetron—HTR1B—GPCR ligand binding—GRM1—bone cancer	0.000246	0.00238	CbGpPWpGaD
Ondansetron—Urticaria—Methotrexate—bone cancer	0.000245	0.00167	CcSEcCtD
Ondansetron—CYP2E1—tendon—bone cancer	0.000245	0.00933	CbGeAlD
Ondansetron—Body temperature increased—Methotrexate—bone cancer	0.000244	0.00166	CcSEcCtD
Ondansetron—Abdominal pain—Methotrexate—bone cancer	0.000244	0.00166	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—bone cancer	0.00024	0.00163	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—bone cancer	0.000238	0.00162	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—bone cancer	0.000238	0.00162	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—bone cancer	0.000238	0.00162	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—bone cancer	0.000236	0.00161	CcSEcCtD
Ondansetron—CYP2E1—spinal cord—bone cancer	0.000236	0.009	CbGeAlD
Ondansetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000234	0.00226	CbGpPWpGaD
Ondansetron—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000231	0.00224	CbGpPWpGaD
Ondansetron—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000231	0.00223	CbGpPWpGaD
Ondansetron—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000231	0.00157	CcSEcCtD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000231	0.00223	CbGpPWpGaD
Ondansetron—Fatigue—Doxorubicin—bone cancer	0.000231	0.00157	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—bone cancer	0.00023	0.00156	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—bone cancer	0.000229	0.00155	CcSEcCtD
Ondansetron—Pain—Doxorubicin—bone cancer	0.000229	0.00155	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—bone cancer	0.000228	0.00155	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—bone cancer	0.000228	0.00155	CcSEcCtD
Ondansetron—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000228	0.00221	CbGpPWpGaD
Ondansetron—Hypersensitivity—Methotrexate—bone cancer	0.000228	0.00155	CcSEcCtD
Ondansetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000224	0.00217	CbGpPWpGaD
Ondansetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000222	0.00215	CbGpPWpGaD
Ondansetron—Asthenia—Methotrexate—bone cancer	0.000222	0.00151	CcSEcCtD
Ondansetron—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000221	0.00214	CbGpPWpGaD
Ondansetron—Feeling abnormal—Doxorubicin—bone cancer	0.00022	0.0015	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—bone cancer	0.000219	0.00149	CcSEcCtD
Ondansetron—Pruritus—Methotrexate—bone cancer	0.000219	0.00149	CcSEcCtD
Ondansetron—OPRM1—GPCR ligand binding—GRM1—bone cancer	0.000217	0.0021	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—GRM4—bone cancer	0.000216	0.00209	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—GNA11—bone cancer	0.000215	0.00207	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—SMO—bone cancer	0.000213	0.00206	CbGpPWpGaD
Ondansetron—Hypersensitivity—Epirubicin—bone cancer	0.000213	0.00145	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—bone cancer	0.000212	0.00144	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—bone cancer	0.000211	0.00144	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—bone cancer	0.000211	0.00144	CcSEcCtD
Ondansetron—Diarrhoea—Methotrexate—bone cancer	0.000211	0.00144	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—bone cancer	0.000207	0.00141	CcSEcCtD
Ondansetron—HTR4—Signaling Pathways—GRM4—bone cancer	0.000206	0.00199	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—RGS1—bone cancer	0.000206	0.00199	CbGpPWpGaD
Ondansetron—Pruritus—Epirubicin—bone cancer	0.000205	0.00139	CcSEcCtD
Ondansetron—Dizziness—Methotrexate—bone cancer	0.000204	0.00139	CcSEcCtD
Ondansetron—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000198	0.00191	CbGpPWpGaD
Ondansetron—Diarrhoea—Epirubicin—bone cancer	0.000198	0.00134	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—bone cancer	0.000197	0.00134	CcSEcCtD
Ondansetron—Vomiting—Methotrexate—bone cancer	0.000196	0.00134	CcSEcCtD
Ondansetron—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000195	0.00189	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—GNA11—bone cancer	0.000195	0.00188	CbGpPWpGaD
Ondansetron—Rash—Methotrexate—bone cancer	0.000195	0.00132	CcSEcCtD
Ondansetron—Dermatitis—Methotrexate—bone cancer	0.000195	0.00132	CcSEcCtD
Ondansetron—HTR4—GPCR downstream signaling—IL3—bone cancer	0.000195	0.00188	CbGpPWpGaD
Ondansetron—Headache—Methotrexate—bone cancer	0.000193	0.00132	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—bone cancer	0.000192	0.0013	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—bone cancer	0.000191	0.0013	CcSEcCtD
Ondansetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00019	0.00183	CbGpPWpGaD
Ondansetron—Pruritus—Doxorubicin—bone cancer	0.000189	0.00129	CcSEcCtD
Ondansetron—HTR1A—GPCR ligand binding—GRM1—bone cancer	0.000188	0.00181	CbGpPWpGaD
Ondansetron—Vomiting—Epirubicin—bone cancer	0.000184	0.00125	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—bone cancer	0.000183	0.00124	CcSEcCtD
Ondansetron—Rash—Epirubicin—bone cancer	0.000182	0.00124	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—bone cancer	0.000182	0.00124	CcSEcCtD
Ondansetron—Headache—Epirubicin—bone cancer	0.000181	0.00123	CcSEcCtD
Ondansetron—OPRM1—TCR Signaling Pathway—JUN—bone cancer	0.00018	0.00175	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—GRM1—bone cancer	0.000179	0.00173	CbGpPWpGaD
Ondansetron—Dizziness—Doxorubicin—bone cancer	0.000177	0.0012	CcSEcCtD
Ondansetron—HTR4—Signaling by GPCR—IL3—bone cancer	0.000177	0.00171	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—SMO—bone cancer	0.000173	0.00168	CbGpPWpGaD
Ondansetron—Vomiting—Doxorubicin—bone cancer	0.00017	0.00116	CcSEcCtD
Ondansetron—Rash—Doxorubicin—bone cancer	0.000169	0.00115	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—bone cancer	0.000168	0.00115	CcSEcCtD
Ondansetron—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000168	0.00162	CbGpPWpGaD
Ondansetron—Headache—Doxorubicin—bone cancer	0.000168	0.00114	CcSEcCtD
Ondansetron—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000167	0.00162	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000165	0.0016	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000165	0.0016	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—GRM4—bone cancer	0.00016	0.00155	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—RGS1—bone cancer	0.00016	0.00155	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—JUN—bone cancer	0.00016	0.00155	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000156	0.00151	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—SMO—bone cancer	0.000153	0.00148	CbGpPWpGaD
Ondansetron—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000147	0.00142	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—RGS1—bone cancer	0.000146	0.00141	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—GRM4—bone cancer	0.000146	0.00141	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000143	0.00139	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000143	0.00138	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—GRM4—bone cancer	0.000142	0.00137	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—RGS1—bone cancer	0.000142	0.00137	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000141	0.00137	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000141	0.00136	CbGpPWpGaD
Ondansetron—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.00014	0.00136	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—GRM1—bone cancer	0.000139	0.00135	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000139	0.00134	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—BRAF—bone cancer	0.000138	0.00133	CbGpPWpGaD
Ondansetron—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000133	0.00129	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—SMO—bone cancer	0.000132	0.00128	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—GRM4—bone cancer	0.000129	0.00124	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—RGS1—bone cancer	0.000129	0.00124	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000128	0.00124	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—GRM1—bone cancer	0.000126	0.00122	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—SMO—bone cancer	0.000126	0.00122	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—GRM1—bone cancer	0.000123	0.00119	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—RGS1—bone cancer	0.000122	0.00118	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—GRM4—bone cancer	0.000122	0.00118	CbGpPWpGaD
Ondansetron—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.00012	0.00116	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000119	0.00115	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000118	0.00114	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000117	0.00113	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000116	0.00112	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000116	0.00112	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—MDM2—bone cancer	0.000116	0.00112	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—GNA11—bone cancer	0.000115	0.00111	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NT5C3A—bone cancer	0.000115	0.00111	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—GRM1—bone cancer	0.000112	0.00108	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—GRM4—bone cancer	0.000111	0.00107	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—RGS1—bone cancer	0.000111	0.00107	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ATF1—bone cancer	0.000107	0.00103	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—GRM1—bone cancer	0.000106	0.00102	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IL3—bone cancer	0.000104	0.00101	CbGpPWpGaD
Ondansetron—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000103	0.000993	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000102	0.000984	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000101	0.000975	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000101	0.000974	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NDUFA12—bone cancer	0.0001	0.000972	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.0001	0.00097	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—JUN—bone cancer	0.0001	0.00097	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NDUFA12—bone cancer	0.0001	0.00097	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	9.95e-05	0.000962	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	9.94e-05	0.000961	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—GRM1—bone cancer	9.62e-05	0.000931	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.09e-05	0.000879	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	9.09e-05	0.000879	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—GNA11—bone cancer	8.97e-05	0.000867	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TGFBR2—bone cancer	8.93e-05	0.000863	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—SMO—bone cancer	8.9e-05	0.000861	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—GSTP1—bone cancer	8.62e-05	0.000833	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RGS1—bone cancer	8.61e-05	0.000832	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—GRM4—bone cancer	8.61e-05	0.000832	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	8.5e-05	0.000822	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IGF1R—bone cancer	8.4e-05	0.000812	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NT5C3A—bone cancer	8.33e-05	0.000805	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NT5C3A—bone cancer	8.31e-05	0.000803	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—GNA11—bone cancer	8.14e-05	0.000787	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—IL3—bone cancer	8.13e-05	0.000786	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—GNA11—bone cancer	7.91e-05	0.000765	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—SMO—bone cancer	7.86e-05	0.00076	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RGS1—bone cancer	7.6e-05	0.000735	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—GRM4—bone cancer	7.6e-05	0.000735	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—GRM1—bone cancer	7.46e-05	0.000722	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL3—bone cancer	7.38e-05	0.000714	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—GNA11—bone cancer	7.19e-05	0.000695	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—IL3—bone cancer	7.17e-05	0.000694	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NDUFA12—bone cancer	7.13e-05	0.000689	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NDUFA12—bone cancer	7.07e-05	0.000684	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—GNA11—bone cancer	6.83e-05	0.00066	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—SMO—bone cancer	6.78e-05	0.000656	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.65e-05	0.000643	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—GRM1—bone cancer	6.59e-05	0.000637	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.56e-05	0.000634	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RGS1—bone cancer	6.56e-05	0.000634	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—GRM4—bone cancer	6.56e-05	0.000634	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL3—bone cancer	6.51e-05	0.00063	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—GNA11—bone cancer	6.2e-05	0.0006	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—IL3—bone cancer	6.19e-05	0.000599	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—KIT—bone cancer	6.09e-05	0.000589	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NDUFA12—bone cancer	6.04e-05	0.000584	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NT5C3A—bone cancer	5.91e-05	0.000571	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NT5C3A—bone cancer	5.86e-05	0.000566	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—BRAF—bone cancer	5.73e-05	0.000554	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—GRM1—bone cancer	5.69e-05	0.00055	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL3—bone cancer	5.62e-05	0.000544	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—EGFR—bone cancer	5.55e-05	0.000537	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SMO—bone cancer	5.26e-05	0.000508	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ENO2—bone cancer	5.04e-05	0.000487	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NT5C3A—bone cancer	5.01e-05	0.000484	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—GNA11—bone cancer	4.81e-05	0.000465	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MDM2—bone cancer	4.8e-05	0.000464	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—DHFR—bone cancer	4.67e-05	0.000452	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NDUFA12—bone cancer	4.66e-05	0.000451	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SMO—bone cancer	4.64e-05	0.000449	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ATF1—bone cancer	4.47e-05	0.000432	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GNA11—bone cancer	4.37e-05	0.000422	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL3—bone cancer	4.36e-05	0.000422	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—GNA11—bone cancer	4.24e-05	0.00041	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—JUN—bone cancer	4.17e-05	0.000403	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MMP9—bone cancer	4.06e-05	0.000392	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SMO—bone cancer	4.01e-05	0.000387	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CYP3A4—bone cancer	3.96e-05	0.000383	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ATF1—bone cancer	3.95e-05	0.000382	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NT5C3A—bone cancer	3.86e-05	0.000374	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL3—bone cancer	3.85e-05	0.000372	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TGFBR2—bone cancer	3.73e-05	0.000361	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—GNA11—bone cancer	3.66e-05	0.000354	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ENO2—bone cancer	3.65e-05	0.000353	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ENO2—bone cancer	3.64e-05	0.000352	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IGF1R—bone cancer	3.51e-05	0.000339	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ATF1—bone cancer	3.41e-05	0.000329	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTP1—bone cancer	3.39e-05	0.000327	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—DHFR—bone cancer	3.38e-05	0.000327	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—DHFR—bone cancer	3.38e-05	0.000326	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL3—bone cancer	3.32e-05	0.000321	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TGFBR2—bone cancer	3.29e-05	0.000318	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EGFR—bone cancer	3.28e-05	0.000317	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GNA11—bone cancer	3.16e-05	0.000306	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GNA11—bone cancer	3.16e-05	0.000305	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IGF1R—bone cancer	3.1e-05	0.000299	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP3A4—bone cancer	2.87e-05	0.000277	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP3A4—bone cancer	2.86e-05	0.000277	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TGFBR2—bone cancer	2.84e-05	0.000275	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—bone cancer	2.75e-05	0.000266	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IGF1R—bone cancer	2.67e-05	0.000258	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ENO2—bone cancer	2.59e-05	0.00025	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ENO2—bone cancer	2.57e-05	0.000248	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KIT—bone cancer	2.54e-05	0.000246	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTP1—bone cancer	2.45e-05	0.000237	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTP1—bone cancer	2.45e-05	0.000237	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—DHFR—bone cancer	2.4e-05	0.000232	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—BRAF—bone cancer	2.39e-05	0.000231	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—DHFR—bone cancer	2.38e-05	0.00023	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—EGFR—bone cancer	2.32e-05	0.000224	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KIT—bone cancer	2.25e-05	0.000217	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GNA11—bone cancer	2.24e-05	0.000217	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GNA11—bone cancer	2.22e-05	0.000215	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ENO2—bone cancer	2.19e-05	0.000212	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—BRAF—bone cancer	2.11e-05	0.000204	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EGFR—bone cancer	2.05e-05	0.000198	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP3A4—bone cancer	2.03e-05	0.000197	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—DHFR—bone cancer	2.03e-05	0.000197	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP3A4—bone cancer	2.02e-05	0.000195	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.01e-05	0.000194	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MDM2—bone cancer	2e-05	0.000194	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KIT—bone cancer	1.94e-05	0.000187	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GNA11—bone cancer	1.9e-05	0.000184	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—BRAF—bone cancer	1.82e-05	0.000176	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MDM2—bone cancer	1.77e-05	0.000171	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—bone cancer	1.77e-05	0.000171	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—bone cancer	1.75e-05	0.00017	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—JUN—bone cancer	1.74e-05	0.000168	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTP1—bone cancer	1.74e-05	0.000168	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTP1—bone cancer	1.72e-05	0.000167	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP3A4—bone cancer	1.72e-05	0.000167	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.71e-05	0.000166	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—bone cancer	1.69e-05	0.000164	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ENO2—bone cancer	1.69e-05	0.000164	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—DHFR—bone cancer	1.57e-05	0.000152	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—JUN—bone cancer	1.54e-05	0.000149	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MDM2—bone cancer	1.53e-05	0.000148	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—bone cancer	1.5e-05	0.000145	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTP1—bone cancer	1.47e-05	0.000143	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GNA11—bone cancer	1.47e-05	0.000142	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—bone cancer	1.37e-05	0.000132	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—JUN—bone cancer	1.33e-05	0.000128	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—bone cancer	1.29e-05	0.000125	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—bone cancer	1.27e-05	0.000123	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—bone cancer	1.27e-05	0.000123	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—bone cancer	1.21e-05	0.000117	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—bone cancer	1.15e-05	0.000111	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTP1—bone cancer	1.14e-05	0.00011	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—bone cancer	1.04e-05	0.000101	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—bone cancer	1.01e-05	9.81e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—bone cancer	9.01e-06	8.72e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—bone cancer	8.94e-06	8.64e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—bone cancer	8.76e-06	8.47e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—bone cancer	7.64e-06	7.38e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—bone cancer	5.89e-06	5.7e-05	CbGpPWpGaD
